Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-Ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2545-2550

  Dean, G Scott ^a   Pusztai, Lajos ^b   Xu, Feng Ji ^b   O'Briant, Kathy ^a   DeSombre, Karen ^a   Conaway, Mark ^a   Boyer, Cinda M ^a   Mendelsohn, John ^b   Bast Jr , Robert C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOTOXIN; ONCOPROTEIN; RICIN A;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOTOXINS; MICE; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RICIN; TUMOR CELLS, CULTURED;

EID: 0031756294     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C., Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
2. Berchuck, A., Rodriguez, G. C., and Kamel, A. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol., 164: 669-674, 1991.
3. Stewart, C. J., Owens, O. J., Richmond, J. A., and McNicol, A. M. Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int. J. Gynecol. Pathol., 11: 266-272, 1992.
4. Bauknecht, T., Runge, M., Schwall, M., and Pfleiderer, A. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol. Oncol., 29: 147-157, 1988.
5. Rubin, S. C., Finstad, C. L., Wong, G. Y., Almadrones, L., Plante, M., and Lloyd, K. O. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am. J. Obstet. Gynecol., 168: 162-169, 1993.
6. cerbB2: increased invasiveness may contribute to poor prognosis. Clin Cancer Res., 3: 1629-1634, 1997.
7. Yu, D., Liu, B., Tan, M., Li, J., Wang, S-S., and Hung, M-C. Overexpression of c-erbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene, 13: 1359-1365, 1996.
8. Kopreski, M. S., Lipton, A., Harvey, H. A., and Kumar, R. Growth inhibition of breast cancer cell lines by combinations of anti-p185HER2 monoclonal antibody and cytokines. Anticancer Res., 16: 433-436, 1996.
9. Kita, Y., Tseng, J., Horan, T., Wen, J., Philo, J., Chan, D., Ratzkin, B., Pacifici, R., Brankow, D., Hu, S., Luo, Y., Wen, D., Arakawa, T., and Nicolson, M. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-HER-2 monoclonal antibodies. Biochem. Biophys. Res. Commun., 226: 59-69, 1996.
10. Wright, M., Grim, J., Deshane, J., Kim, M., Strong, T. V., Siegal, G. P., and Curiel, D. T. An intracellular anti-erb-B-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther., 4: 317-322, 1997.
11. Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., and Ullrich, A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
12. Stancovski, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y., and Sela, M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA, 88: 8691-8695, 1991.
13. Scott, G. K., Dodson, J. M., Montgomery, P. A., Johnson, R. M., Sarup, J. C., Wong, W. L., Ullrich, A., Shepard, H. M., and Benz, C. C. p185HER2 signal transduction in breast cancer cells. J. Biol. Chem., 266: 14300-14305, 1991.
14. Tagliabue, E., Centis, F., Campiglio, M., Mastroianni, A., Martignone, S., Pellegrini, R., Casalini, P., Lanzi, C., Menard, S., and Colnaghi, M. I. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int. J. Cancer, 47: 933-937, 1991.
15. Kasprzyk, P. G., Song, S. U., Di Fiore, P. P., and King, C. R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res., 52: 2771-2776, 1992.
16. Xu, F. J., Lupu, R., Rodriguez, G. C., Whitaker, R. S., Boente, M. P., Berchuck, A., Yu, Y., DeSombre, K. A., Boyer, C., and Bast, R. C., Jr. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2) gene product p185. Int. J. Cancer, 53: 401-408, 1993.
17. Rodriguez, G. C., Boente, M. P., Berchuck, A., Whitaker, R. S., O'Briant, K. C., Xu, F., and Bast, R. C., Jr. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am. J. Obstet. Gynecol., 168: 228-232, 1993.
18. De Santes, K., Slamon, D., Anderson, S. K., Shepard, M., Fendly, B., Maneval, D., and Press, O. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res., 52: 1916-1923, 1992.
19. Maier, L. A., Xu, F. J., Hester, S., Boyer, C., McKenzie, S., Bruskin, A. M., Argnon, Y., and Bast, R. C. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res., 51: 5361-5369, 1991.
20. Crews, J. R., Maier, L. A., Yu, Y. H., Hester, S., O'Briant, K., Leslie, D. S., DeSombre, K., George, S. L., Boyer, C. M., Argon, Y., and Bast, R. C., Jr. A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. Int. J. Cancer, 51: 772-779, 1992.
21. Weis, W., Harwerth, I. M., Mueller, M., Groner, B., and Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res., 52: 6310-6317, 1992.
22. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., and King, C. R. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867-5871, 1992.
23. Tecce, R., Digiesi, G., Savarese, A., Trizio, D., and Natali, P. G. Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins. Int. J. Cancer, 55: 122-127, 1993.
24. Bast, R. C., Jr., Kerns, B. J., MacDonald, J. A., Jordan, P. A., Boyer, C. M., Mendelsohn, J., and Berchuck, A. Coexpression of the C-erbB-2 (HER-2/neu) gene product (P185) and epidermal growth factor receptor (p170) on epithelial ovarian cancers and normal tissues. Hydridoma, in press, 1998.
25. Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., and Mendelsohn, J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 44: 1002-1007, 1984.
26. Masui, H., Kamrath, H., Apell, G., Houston, L. L., and Mendelsohn, J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res., 49: 3482-3488, 1989.
27. Ozawa, S., Ueda, M., Ando, N., Abe, O., Minoshima, S., and Shimizu, N. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int. J. Cancer, 43: 152-157, 1989.
28. Hirota, N., Ueda, M., Ozawa, S., Abe, O., and Shimizu, N. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res., 49: 7106-7109. 1989.
29. McKenzie, S. J., Marks, P. J., Lam, T., Morgan, J., Panicali, D. L., Trimpe, K. L., and Carney, W. P. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene, 4: 543-548, 1989.
30. Bjorn, M. J., Ring, D., and Frankel, A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res., 45: 1214-1221, 1985.
31. Ring, D. B., Clark, R., and Saxena, A. Identity of BCA200, and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. Mol. Immunol., 28: 915-917, 1991.
32. Masui, H., Kamrath, H., Apell, G., Houston, L. L., and Mendelsohn, J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res., 49: 3482-3488, 1989.
33. Yu, Y. H., Crews, J. R., Cooper, K., Ramakrishnan, S., Houston, L. L., Leslie, D. S., George, S. L., Lidor, Y., Boyer, C. M., Ring, D. B., and Bast, R. C., Jr. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res., 50: 3231-3238, 1990.
34. Fraker, P. J., and Speck, J. C., Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun., 80: 849-857, 1978.
35. Johnson, E. A., and Brown, B. W. The Spearman estimator for serial dilution assays. Biometrics, 27: 79-88, 1961.
36. Steel, G. G., and Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5: 85-91, 1979.
37. Robertson, T., Wright, F. T., and Dykstra, R. L. (eds.). Order Restricted Statistical Inference. New York: Wiley, and Sons, 1988.
38. Neter, J., Wasserman, W., and Kutner, M. (eds.). Applied Linear Statistical Models. Homewood, IL: Richard Irwin, Inc., 1985.
39. Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Parker, M. G., Sliwkowski, M. X., and Slamon, D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 10: 2435-2446, 1995.
40. Xie, W., Su, K., Wang, D., Paterson, A. J., and Kudlow, J. E. MDA 468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21WAF1. Anticancer Res., 17: 2627-2633, 1997.
41. Maier, L., Xu, F-J., Hester, S., Boyer, C. M., McKenzie, S., Bruskin, A. M., Argon, Y., and Bast, R. C. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erb-B-2. Cancer Res., 51: 5361-5369, 1991.
42. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.